AMSBIO has announced the launch of Newborn Human Foreskin Fibroblasts qualified for induced Pluripotent Stem Cell (iPSC) reprogramming.
[More]
New findings reveal the surprisingly complex protein-coding capacity of the human cytomegalovirus, or HCMV, and provide the first steps toward understanding how the virus manipulates human cells during infection. The genome of the HCMV was first sequenced over 20 years ago, but researchers have now investigated the proteome-the complete set of expressed proteins-of this common pathogen as well.
[More]
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
[More]
Stanford University School of Medicine scientists have demonstrated, in a study conducted jointly with researchers at Yale University, that induced-pluripotent stem cells - the embryonic-stem-cell lookalikes whose discovery a few years ago won this year's Nobel Prize in medicine - are not as genetically unstable as was thought.
[More]
Cancers arise when a normal cell acquires a mutation in a gene that regulates cellular growth or survival. But the particular cell this mutation happens in-the cell of origin-can have an enormous impact on the behavior of the tumor, and on the strategies used to treat it.
[More]
Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.
[More]
Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.
[More]
By reprogramming skin cells from Parkinson's disease patients with a known genetic mutation, researchers at the Salk Institute for Biological Studies have identified damage to neural stem cells as a powerful player in the disease.
[More]
A study by UT Southwestern Medical Center researchers finds that a starvation hormone markedly extends life span in mice without the need for calorie restriction.
[More]
Using a newly discovered cell technology, Georgetown University Medical Center researchers were able to identify an effective therapy for a patient with a rare type of lung tumor. The single case study, reported in the September 27 issue of New England Journal of Medicine, provides a snapshot of the new technology's promising potential; however, researchers strongly caution that it could be years before validation studies are completed and regulatory approval received for its broader use.
[More]
Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.
[More]
Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF).
[More]
Scientists have successfully treated chronic diabetic foot ulcers using skin grafts grown from individual patient cell samples.
[More]
The primitive stem cell state we created is called an “induced pluripotent stem cell” (iPSC). iPSC are a new, unique, and artificially-created type of stem cell that were first described in 2006 by a Japanese scientist named Shinya Yamanaka.
[More]
Cardiac injury leads to significant structural changes in the heart, including enlargement, excess formation of fibrous growth tissue, and abnormalities of the coronary vasculature. While associated factors have been targeted for therapeutic intervention, the results have been conflicting. Most studies have investigated these changes after six days of injury. However, advanced stages of remodeling have already begun by day seven following injury.
[More]
Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.
[More]
Depression takes a substantial toll on brain health. Brain imaging and post-mortem studies provide evidence that the wealth of connections in the brain are reduced in individuals with depression, with the result of impaired functional connections between key brain centers involved in mood regulation. Glial cells are one of the cell types that appear to be particularly reduced when analyzing post-mortem brain tissue from people who had depression.
[More]
Despite years of research, glioblastoma, the most common and deadly brain cancer in adults, continues to outsmart treatments targeted to inhibit tumor growth.
[More]
Interface zone fibroblasts in gastric adenocarcinoma promote the invasion, migration, and proliferation of cancer cells, as well as prevent apoptosis, to a greater degree than normal or tumor zone fibroblasts, say researchers.
[More]
Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors - such as those of the breast, prostate, lung and colon - that have metastasized, or spread, throughout the body. A team of scientists led by Fred Hutchinson Cancer Research Center has discovered a key factor that drives this drug resistance - information that ultimately may be used to improve the effectiveness of therapy and buy precious time for patients with advanced cancer.
[More]